New drug may stop relapse after transplant for rare blood cancers

NCT ID NCT06543381

First seen Mar 10, 2026 · Last updated May 16, 2026 · Updated 8 times

Summary

This early-stage trial tests a pill called olutasidenib in people with certain blood cancers (AML, MDS, or CMML) who have an IDH1 gene change. The goal is to see if taking this drug after a donor stem cell transplant is safe and can help prevent the cancer from coming back. About 15 adults will take part, and researchers will monitor side effects and how long they can stay on the treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • City of Hope Medical Center

    RECRUITING

    Duarte, California, 91010, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Cleveland Clinic Cancer Center

    NOT_YET_RECRUITING

    Cleveland, Ohio, 44195, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.